Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | FABP3 | P05413 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3342009 | 0.91 | LDHA (0.42) | LDHATP53HTT | |
| SCHEMBL3341188 | 0.90 | LDHA (0.46) | LDHATP53HTTDHODH | |
| SCHEMBL3342027 | 0.88 | KMO (0.48) | KMOLDHATP53HTTDHODH | |
| SCHEMBL3341836 | 0.86 | KMO (0.50) | KMOLDHATP53HTT | |
| SCHEMBL3342587 | 0.86 | KMO (0.47) | KMOLDHA | |
| SCHEMBL3342166 | 0.85 | CSNK1D (0.47) | TP53HTT | |
| SCHEMBL3344293 | 0.84 | KMO (0.46) | KMODHODH | |
| SCHEMBL3340026 | 0.81 | LDHA (0.51) | LDHATP53HTTDHODH | |
| SCHEMBL3343592 | 0.81 | KMO (0.46) | KMOTP53HTTDHODH | |
| SCHEMBL5115225 | 0.80 | TDP1 (0.56) | FABP3FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-06-24 | — | — | US | disclosed |
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-06-24 | — | — | US | disclosed |
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-06-24 | — | — | US | disclosed |
| WO-2008031500-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | PPARA, PPARD, PPARG | KMO 1885/4885LDHA 3407/4885FABP3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.